Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.

J Eur Acad Dermatol Venereol · 2017 · PMC5363239 · PMID 27538241

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Mean change in SF‐36v2 PCS score, although numerically greater with apremilast than with placebo, did not reach statistical significance or the MCID threshold at Week 16 (Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.